Current Headlines

  1. Study Shows Whole-Cell Vaccine Was More Effective Than Acellular Vaccine During California Pertussis Outbreak
    5/20/2013

    Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.

  2. The Start-Up Elsalys Biotech, A New Player In The Therapeutic Monoclonal Antibody Arena, Announces The First Round Of Financing With Transgene And Sofimac Partners
    5/17/2013

    ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.

  3. Seminars, Technology Highlight CYTO 2013 Offerings From Beckman Coulter Life Sciences
    5/16/2013

    Presenting two seminars and seven poster sessions, Beckman Coulter Life Sciences will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

  4. MultiCell Technologies Files U.S. Patent Application For Targeted Delivery Of Noncoding Micro RNAs For The Treatment Of Liver Cancer
    5/16/2013

    MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death.  MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.

  5. AbbVie To Present Data On Investigational Anti-Cancer Compounds At American Society Of Clinical Oncology Annual Meeting
    5/15/2013

    AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago.

  6. ILC Dover Receives ISO Class 7 Cleanroom Certification
    5/15/2013

    ILC Dover, the designer and manufacturer of NASA’s space suits and a wide range of engineered film and fabric products, announced recently it has received certification for its ISO Class 7 Clean Room.

  7. Global Vision Selected By Pfizer For Worldwide Deployment Of Automated Proofreading Solutions
    5/14/2013

    Global Vision, the industry leader in the development of automated proofreading solutions, recently announced that it has been selected by Pfizer for worldwide deployment as its proofreading technology solution provider.

  8. NanoPass Technologies Supports A CDC-Sponsored Phase 3 Study Of Polio Vaccine In Infants As Part Of its Global Health Initiative
    5/13/2013

    NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East Asia.

  9. U.S. FDA Grants Priority Review To Simeprevir (TMC435) For Combination Treatment Of Genotype 1 Chronic Hepatitis C
    5/13/2013

    Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.

  10. BioTek Responds To Growing AP Market Needs With New Taiwan Office
    5/13/2013

    BioTek Instruments, Inc., continues their expansion in the Asia Pacific region with the opening of BioTek Taiwan, located in the Neihu District of Taipei. Mr. Jack Lu (Lu Wen-Chung), previously with Tseng Hsiang Life Science, was named General Manager of BioTek Taiwan at its inception in mid-April.